OBJECTIVE To compare clinical efficacy ,safety and impact on personal and social function of pali-peridonewitharipiprazoleintreatmentoffemalefirst-episodeschizophrenia.METHODS 72casesoffemalefirst episode schizophrenic patients were randomly divided into paliperidone group (36 cases) and the aripiprazole group (36 cases) and treated for 10 weeks.Positive and Negative Syndrome Scale ( PANSS) ,personal and social function Scale ( PSP) were used to evaluate the efficacy .Treatment emergent symptom scale ( TESS ) were used to assessed the safety.RESULTS The 2 ,4 ,8 ,10 weekend PANSS scores were significantly lower than baseline in two groups ( P0.05).The 10 weekend PSP scores were significantly lower than baseline in two groups (P<0.05).PSP scores were significantly higher in paliperidone・ 96・group than in aripiprazole group (P<0.05).Two adverse reactions were mild to moderate.but the type and extent of adverse reactions were various .CONCLUSION paliperidone and aripiprazole had good efficacy and few adverse reactions in treatment of female first-episode schizophrenia .Paliperidone had rapid onset and was better in personal and social function recovery .%目的：比较帕利哌酮与阿立哌唑治疗女性首发精神分裂症的临床疗效、安全性、个人和社会功能的影响。方法将72例女性首发精神分裂症患者随机分为帕利哌酮组和阿立哌唑组，各36例，疗程10周，采用阳性和阴性综合征量表（ PANSS）、个人和社会功能量表（ PSP）评定疗效，采用治疗中需处理的不良反应症状量表（ TESS）评定安全性。结果治疗第2、4、8、10周末两组 PANSS各项评分均较治疗前降低，差异有统计学意义（ P＜0．05或P＜0．01），两组间PANSS减分在治疗2周末比较差异有统计学意义（ P＜0．05）。两组患者总有效率比较，帕利哌酮组为86．1％，阿立哌唑组为83．3％，疗效差异无统计学意义（ P＞0．05）。治疗10周末时两组PSP值均比治疗前显著增高（ P＜0．05），组间比较帕利哌酮组明显高于阿立哌唑组（ P＜0．05）。两组不良反应均为轻至中度，但种类与程度有所不同。结论帕利哌酮与阿立哌唑治疗女性首发精神分裂症均具有疗效好、不良反应少的特点。帕利哌酮起效较快，个人和社会功能恢复较好。
展开▼
